Virtual Library
Start Your Search
J. Li
Author of
-
+
P2.03a - Poster Session with Presenters Present (ID 464)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03a-019 - A Retrospective Analysis Of Nanoparticle Albumin Bound Paclitaxel In Chinese Patients With Recurrent Advanced Non-small Cell Lung Cancer In A Single Center (ID 4068)
14:30 - 14:30 | Author(s): J. Li
- Abstract
Background:
This is the first report describing the safety and short-term efficacy of nanoparticle albumin bound paclitaxel (Nab-PTX) as monotherapy administered weekly in the treatment of Chinese patients with recurrent advanced non-small cell lung cancer (NSCLC), and analyzing potential factors that may affect prognosis.
Methods:
Patients with recurrent advanced NSCLC who received an weekly nab-paclitaxel regimen (130 mg/m2/week) treatment were eligible.Toxicity and response according to the RECIST criteria were summarized in the study. Classification and regression tree (CART) analysis was performed to estimate the effect of variables (age, gender, performance score, smoking, clinic stage, pathological type, previous line of therapy, treatment cycles, EGFR status, EGFR-/ALK-TKIs, SPARC expression) on PFS. The Kaplan–Meier analysis was used to estimate the effect of terminal tree notes.
Results:
A total of 104 patients were included in the study from June 2010 to March 2014 in the Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences,. The median follow-up period was 9.56 months (0.92-34.00 months). The overall response rate was 21.4%, and the disease control rate was 73.8%. The median PFS was 4.53 months (95% CI: 3.518- 5.542), and the median OS was 12.53 months (95% CI: 10.502- 14.558). Grade 3 adverse events were neutropenia (8.8%), peripheral neuropathy (4.8%), myalgia/arthralgia (4.0%), and fatigue (1.9%), respectively. Grade 4 toxicities rarely occured except neutropenia (1.0%). CART analysis identified 4 terminal nodes based on therapy cycles, age and therapy line. In the four subsets, those with ＜ 4 therapy cycles had the lowest PFS (Median: 1.80 months). Those with ≥ 4 cycles and age ≥70 years had the longest PFS (Median: 8.83 months). The median PFS was significantly different between the four subgroups (P =0.000). In addition, PFS in the ≥ 4 therapy cycles group was better than the without group (Median: 6.23 vs. 1.80 months, P=0.000). No PFS significant differences were observed for both age (≥70 years vs ＜70 years; Median: 8.83vs. 5.87 months, P=0.06) and lines of therapy (＞third-line vs ≤ third-line; Median: 6.37 vs 4.60, P=0.063). A trend of a benefit in PFS in favor of ≥70 years age and ＞third-line groups was found in our treatment.
Conclusion:
The weekly Nab-PTX regimen was effective and well-tolerated in patients with recurrent advanced NSCLC. Treatment cycles factors may be used to predict the therapeutic efficacy of Nab-PTX. Nab-PTX was also found the favourable survival benefit in older population (aged ≥70 years) and patients with ＞third-line therapy.
